People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons ...

Aliyah Lofton Promising review: "As embarrassing as it is to admit, I used this in the car on a road trip. I didn't know ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

An ear, nose and throat doctor explains why tipping your head back with a nosebleed could make things worse and what you ...